JPRN-UMIN000045097已完成未知
Prospective study on evaluation of immunological response after SARS-CoV-2 vaccination - Prospective study on evaluation of immunological response after SARS-CoV-2 vaccination
Shionogi & Co., Ltd.0 个研究点目标入组 205 人开始时间: 2021年8月9日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 205
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. For male, those who more than 200 mL of their whole blood or blood component has been lost within 12 weeks before consent acquisition, or those who more than 100 mL of their whole blood or blood component has been lost within 4 weeks before consent acquisition. For female, those who more than 200 mL of their whole blood or blood component has been lost within 16 weeks before consent acquisition, or those who more than 100 mL of their whole blood or blood component has been lost within 4 weeks before consent acquisition. 2. Those who participated in other clinical studies within 30 days before consent acquisition, or are participating in other clinical studies except for "Observational study on the evaluation of COVID-19 prevention and subjects' health status after SARS-CoV-2 vaccination" conducted by Shionogi & Co., Ltd.
研究者
相似试验
已完成
不适用
Prospective study on evaluation of immune response after SARS-CoV-2 vaccinatioHealthy SubjectJPRN-UMIN000045492Shionogi & Co., Ltd.143
进行中（未招募）
1 期
A prospective study to evaluate the immune response of UK infants receiving the 13-valent pneumococcal conjugate vaccine as part of their routine primary immunisation schedule at 2 and 4 months (code: P13UK) - P13UKPrevenar13 was introduced into the national childhood immunisation programme to prevent serious bacterial infections caused by the germ Streptococcus pneumonia, including meningitis, septicaemia and pneumonia.EUCTR2010-023865-22-GBHealth Protection Agency
已完成
4 期
Responses to booster vaccinations in UK toddlersISRCTN84763401Health Protection Agency (UK)200
已完成
4 期
Influenza Specific Immunity After Vaccination in Recipients of Haematopoietic Stem Cell Transplantation Compared to Healthy ControlsHaematopoietic Stem Cell Transplant patientshaematological malignancyAutologous or allogeneicCancer - Any cancerInfection - Other infectious diseasesInflammatory and Immune System - Other inflammatory or immune system disorderscancerInfluenzaACTRN12614000240640Princess Margaret Hospital for children150
进行中（未招募）
1 期
Effect of rituximab in secondary progressive multiple sclerosisMultiple SclerosisEUCTR2012-004436-36-DKOdense University Hospital15